

## EICADD Center Ajman

### Director's Developmental Progress Assessment Report

**Date of Visit:** 20-11-2025

**Child's Name:** KHALIFA AHMED OBAID MOHAMMAD ALFALASI

**Date of Birth:** 2015-09-19

**Gender:** Male

**Guardian:** AHMED OBAID MOHAMMAD ALFALASI

#### Overview

Khalifa visited our center for a developmental progress assessment. During the evaluation, he demonstrated **Information Processing Delays** and **global developmental delays**, which are contributing to **features of autism**. These findings correlate with the **variants affecting brain development and behaviour** that were shown in the **previous analyses presented on the day of the assessment**.

Khalifa also has **seizures**, in addition to a **positive MRI showing brain abnormalities**, further supporting the presence of neurodevelopmental involvement. A **mutation in the FGFR3 gene** was identified; however, according to current medical databases, children with FGFR3 mutations typically do **not** share the same phenotype as Khalifa. This discrepancy strongly indicates that **another biological cause may be contributing to his developmental challenges**, requiring further analysis.

This report is **not a final diagnosis**, but a developmental assessment reflecting Khalifa's current neurodevelopmental profile based on observed findings and previously conducted analyses.

#### Recommended Plan

### 1. Development Protocol for Information Processing

- Continue the protocol for **4 months**, followed by reevaluation **preferably in person**.
- Reevaluate the intervention plan and establish a detailed **baseline** during the next assessment.
- Continue with the structured intervention plan to support processing abilities, behavioural regulation, and cognitive development.

### 2. Main Recommended Analyses (Through Neurazon – Canada)

**The recommended tests are conducted through Neurazon (Canada), a bioinformatics company partnered with certified international laboratories. These tests are external, optional, and not performed directly through our centers. Please refer to the Neurazon plan for further details.**

### 3. Recommended Therapy

#### A. Rehabilitation Therapy

- **Plasticity Rehabilitation Therapy:**  
Recommended **2–3 sessions per week**, to begin **after the 4-month protocol period**.  
It is advised to **book in advance** to secure appropriate time slots in four months.

#### Notes on External Testing

All recommended analyses above are conducted **exclusively through Neurazon (Canada)**, an external bioinformatics center partnered with internationally accredited laboratories. These tests are **recommendations**, not mandatory, and are not conducted directly through the EICADD Center.

#### Conclusion

This assessment is **not a final diagnosis**, but a developmental evaluation based on current information. Khalifa's delays are driven by neurodevelopmental variants, seizures, and MRI abnormalities, with possible additional biological contributors requiring further investigation. With structured therapy and adherence to the recommended plan, improvement is possible, and the child is open to developmental progress.

#### Disclaimer

This assessment is valid for **4 months** from the date of evaluation.  
Findings may change as the child develops and responds to intervention.  
All recommended tests are external, optional, and processed solely through **Neurazon (Canada)**.

#### Centers' Leading Staff:

**Speech Therapist:** Ms. Amira Alomari

**Occupational Therapist:** Ms. Malak Jaber

**Psychologist and behaviour therapist (Ajman):** Ms. Asmaa Alshanawi

**EICADD Center Director**

A handwritten signature in black ink, likely belonging to Dr. Noraldin, is written over a circular stamp. The stamp contains the EICADD logo and the text 'Early Intervention Center for Autism and Developmental Disorders' in both Arabic and English.